Brief Summary
Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advancedat a late stage, far along PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.
Intervention / Treatment
- Drug: IMC-P115C
Inclusion Criteria:
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status score of 0 or 1
- HLA-A*02:01-positive
- Meeting PRAME-positive tumor testing requirements
- Metastatic or unresectable solid tumors
- Have received (or be receiving), relapsed from, be refractory to or intolerant of all therapies
- Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control